Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD:: a discrimination from Alzheimer's disease?

被引：113

作者：

Kapaki, E ^{[1
]}

Kilidireas, K ^{[1
]}

Paraskevas, GP ^{[1
]}

Michalopoulou, M ^{[1
]}

Patsouris, E ^{[1
]}

机构：

[1] Athens Natl Univ, Aeginit Hosp, Sch Med, Dept Neurol, Athens 11528, Greece

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2001年 / 71卷 / 03期

关键词：

Creutzfeldt-Jakob disease; Alzheimer's disease; tau protein; beta-amyloid; 1-42;

D O I：

10.1136/jnnp.71.3.401

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The aim was to quantify tau protein and beta -amyloid (A beta 42) in the CSF of patients with sporadic Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), and controls. Double sandwich enzyme linked immunosorbent assays (ELISAs) were used for measurments. Tau was increased 58-fold in CJD and 3.5-fold in AD compared with controls, whereas A beta 42 was decreased 0.5-fold in both CJD and AD. A cut off level for tau protein at 2131 pg/ml successfully discriminated CJD from AD (100% specificity and 93% sensitivity). Tau protein concentration in CSF is probably an additional useful marker in differentiating CJD from AD.

引用

页码：401 / 403

页数：3

共 50 条

[31] Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease
Shea, Yat Fung
Chu, Leung-wing
Mok, Ming-yee Maggie
Lam, Man-Fai
[J]. JOURNAL OF NEPHROLOGY, 2014, 27 (02) : 217 - 220
[32] In vitro and in vivo protein oxidation induced by Alzheimer's disease amyloid β-peptide (1-42)
Butterfield, DA
Yatin, SM
Link, CD
[J]. OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS, 1999, 893 : 265 - 268
[33] Increased CSF amyloid beta protein 1-38 (Aβ38)/Aβ42 ratio in Alzheimer disease
Mehta, PD
Pirttila, T
[J]. NEUROLOGY, 2005, 64 (06) : A68 - A68
[34] Clinical use and analytical problems in amyloid-beta(1-42) and tau protein in cefalorachidic fluid as markers of Alzheimer's disease
Kang, Ju-Hee
Korecka, Magdalena
Toledo, Jon B.
Trojanowski, John Q.
Shaw, Leslie M.
[J]. BIOCHIMICA CLINICA, 2014, 38 (03) : 255 - 267
[35] CSF amyloid β 1-42 predicts cognitive decline in Parkinson's disease
Siderowf, A.
Xie, S. X.
Hurtig, H. I.
Weintraub, D.
Duda, J. E.
Chen-Plotkin, A.
Shaw, L. M.
Van Deerlin, V.
Trojanowski, J. Q.
Clark, C. M.
[J]. MOVEMENT DISORDERS, 2010, 25 (07) : S205 - S205
[36] Amyloid-β(1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease
Mulder, Cees
Verwey, Nicolaas A.
van der Flier, Wiesje M.
Bouwman, Femke H.
Kok, Astrid
van Elk, Evert J.
Scheltens, Philip
Blankenstein, Marinus A.
[J]. CLINICAL CHEMISTRY, 2010, 56 (02) : 248 - 253
[37] Decreased serum amyloid β1-42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1-42 peptide
Brettschneider, S
Morgenthaler, NG
Teipel, SJ
Fischer-Schulz, C
Bürger, K
Dodel, R
Du, YS
Möller, HJ
Bergmann, A
Hampel, H
[J]. BIOLOGICAL PSYCHIATRY, 2005, 57 (07) : 813 - 816
[38] Amyloid β peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology
Attems, J
Lintner, F
Jellinger, KA
[J]. ACTA NEUROPATHOLOGICA, 2004, 107 (04) : 283 - 291
[39] Alzheimer's disease:: β-amyloid protein and tau
Morishima-Kawashima, M
Hara, Y
[J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 70 (03) : 392 - 401
[40] Relationship between apoE genotype and CSF β-amyloid (1-42) and tan in patients with probable and definite Alzheimer's disease
Tapiola, T
Pirttilä, T
Mehta, PD
Alafuzoff, I
Lehtovirta, M
Soininen, H
[J]. NEUROBIOLOGY OF AGING, 2000, 21 (05) : 735 - 740

← 1 2 3 4 5 →